Baidu
map

Immunity:免疫检查点调节因子为肿瘤免疫治疗提供新靶点

2016-05-29 佚名 生物谷

最近,美国科学家发现了一种新的免疫应答调控因子,在这篇发表在国际学术期刊Immunity上的文章中,研究人员还对于T细胞为何无法清除慢性感染,消除肿瘤细胞的原因进行了解读。这些研究发现为许多临床背景下的T细胞应答调节开辟了新的道路。   T细胞是负责识别并清除特异性入侵者的免疫细胞,它们的活性受到高度调控--来自其他细胞的信号会调节T细胞应答进而对抗病原体。但是有时候这些应

最近,美国科学家发现了一种新的免疫应答调控因子,在这篇发表在国际学术期刊Immunity上的文章中,研究人员还对于T细胞为何无法清除慢性感染,消除肿瘤细胞的原因进行了解读。这些研究发现为许多临床背景下的T细胞应答调节开辟了新的道路。
 
T细胞是负责识别并清除特异性入侵者的免疫细胞,它们的活性受到高度调控--来自其他细胞的信号会调节T细胞应答进而对抗病原体。但是有时候这些应答很快就会消失,比如慢性病毒感染或癌症都会通过诱导T细胞紊乱导致免疫应答受阻。
 
近来一些阻断免疫检查点的新型药物的出现为肺癌以及黑色素瘤等特定类型癌症的治疗提供了新的改进方法。免疫检查点的作用类似于T细胞的制动系统,能够限制免疫系统对自身健康细胞进行攻击,防止自身免疫疾病的发生。
 
在这项研究中,研究人员发现一种叫做PSGL-1的分子能够增加免疫检查点水平,进而抑制T细胞活性。当PSGL-1发生缺失,T细胞的制动系统解除,T细胞就能够保持活跃状态。他们利用PSGL-1无应答小鼠进行研究发现这些小鼠能够完全根除淋巴细胞性脉络丛脑膜炎病毒(LCMV)的感染,而在正常情况下LCMV感染会持续数月。
 
随后,研究人员又将黑色素瘤细胞注射到模型小鼠体内,观察这种免疫制动分子的缺失是否能够影响癌症发展,结果发现模型小鼠体内的肿瘤生长明显慢于正常小鼠,这表明PSGL-1对T细胞应答具有重要的调控作用。
 
研究人员表示,阻断PSGL-1或可增强机体对癌症以及慢性病毒感染的免疫应答,而激活PSGL-1则可以帮助抑制免疫应答,或可用于类风湿性关节炎,牛皮癣,多发性硬化以及系统性红斑狼疮等自身免疫疾病的治疗。目前许多药物公司对该分子表示出极大兴趣,希望进一步开发其在临床方面的应用。研究人员认为PSGL-1抑制剂将会成为癌症免疫治疗的新工具,为无法从其他检查点抑制剂获得治疗效果的病人带来新的福音。
  
原始出处
 
Roberto Tinoco1, 2, Florent Carrette1, Monique L. Barraza1, Dennis C. Otero1, Jonathan Maga?a1, Marcus W. Bosenberg3, Susan L. Swain4, Linda M. Bradley.PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.Immunity.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-06-03 yde2801fm***3926(暂无匿称)

    学习了,免疫治疗是新的治疗方向,值得深入学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-06-02 mym86538653

    想看全文

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-06-02 mym86538653

    思路不错 新方向

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 lsndxfj
  7. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2030307, encodeId=d9fc203030e6f, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Jan 31 19:21:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969250, encodeId=85461969250ac, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Feb 13 09:21:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88324, encodeId=e55e88324af, content=学习了,免疫治疗是新的治疗方向,值得深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Fri Jun 03 07:51:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88217, encodeId=9d788821eec, content=想看全文, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:33:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88216, encodeId=fea9882163f, content=思路不错 新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:27:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288168, encodeId=a02f1288168f3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340467, encodeId=c9f0134046ea6, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Tue May 31 02:21:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87657, encodeId=5c2b8e657f3, content=确实不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-30 lsblb

    确实不错

    0

相关资讯

肿瘤免疫治疗:未来发展这路

    美国的肿瘤免疫治疗研究与实践一直走在世界的前列。在9月14日召开的2011年中国临床肿瘤学会(CSCO)学术年会上,美国癌症免疫治疗学会(SITC)与CSCO首次举行了联合学术专场,受邀演讲的美国研究者带来了肿瘤免疫治疗最前沿的进展。本报记者特别采访了几位讲者,请他们分享了对肿瘤免疫治疗现状的认识以及对未来的思考与展望。   Fox 博士:“免疫系统就像一个黑盒子,

T细胞与肿瘤免疫治疗:下一个诺贝尔奖热门?

与手术、放疗和化疗等传统手段明显不同,肿瘤的免疫治疗,对人类健康和生物产业而言是一场“革命”。有不少业内人士认为,这一领域的成功可能在近几年获得诺贝尔奖。那么,该领域的功臣是谁?其科学基础又是什么? 董晨(清华大学免疫学研究所教授) 近几年,有关肿瘤免疫治疗的好消息不断传来。一系列成果的出现,使美国《科学》杂志在2013年把肿瘤免疫治疗推为当年最大的科学突破。 有几项进展格外引人瞩目

AACR 2015现场报道:美国癌症研究会年会肿瘤免疫治疗重点

今天是美国癌症研究会2015年年会第一天,会议安排了4场关于肿瘤免疫治疗的大型的学术活动。内容主要包括以下几个方面:一、围绕检测点阻断治疗探讨进一步提高疗效的方法,寻找能够预测检测点治疗疗效的生物学标志物,以及探索为什么这一疗法在一些肿瘤当中疗效不好的原因比如结肠癌;二、介绍了肿瘤治疗性疫苗研究的最新进展以及提高疗效的策略;三、针对对免疫功能具有抑制作用的肿瘤微环境的治疗策略,主要涉及三个方面;I

亿万富豪医生陈颂雄:面对癌症,我们过于天真!

陈颂雄拥有诸多身份,大家最熟知的前缀是亿万富豪或者承诺向盖茨基金会捐出至少一半资产的慈善家,而本质上,他其实是医生出身,所以才对癌症治疗付诸了如此多的热情。24岁他获得医学博士学位,39岁他选择离开医疗系统选择创业,开办了一家糖尿病药品公司。后来,他把目标聚焦癌症领域,成功研究出无溶剂型抗癌药——紫杉醇纳米制剂。它不但比当时的抗癌药泰素疗效高出一倍,而且副作用更小。2005年经FDA批准,紫杉

盘点:肿瘤免疫治疗新近进展

肿瘤免疫治疗是应用免疫学原理和方法,提高肿瘤细胞的免疫原性和对效应细胞杀伤的敏感性,激发和增强机体抗肿瘤免疫应答,并应用免疫细胞和效应分子输注宿主体内,协同机体免疫系统杀伤肿瘤、抑制肿瘤生长。肿瘤免疫治疗近来备受关注,是肿瘤治疗领域的焦点。今天小编就带大家回顾一下过去一段时间肿瘤免疫研究领域都有哪些最新进展。     1.JEM:新研究为肿瘤免疫治疗抗体开发找到新

Baidu
map
Baidu
map
Baidu
map